ID
22685
Description
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus
Mots-clés
Versions (2)
- 7/6/17 7/6/17 -
- 9/6/17 9/6/17 -
Téléchargé le
9 de junio de 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
STUDY DRUG ADMINISTRATION DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330
STUDY DRUG ADMINISTRATION DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330
Similar models
STUDY DRUG ADMINISTRATION DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330
C0229089 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0229090 (UMLS CUI [2,2])
C0032042 (UMLS CUI [2])
C0011008 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])
C0042164 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0234632 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0578862 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C2880797 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C3714514 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0038901 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])